Biotech News

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Sensei Biotherapeutics (SNSE)Sensei Biotherapeutics2026-06-25 13:46 ESTEarnings

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025.

Open original release

Related news

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SNSESensei Biotherapeutics2026-06-26 08:50 EST

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSESensei Biotherapeutics2026-06-26 08:50 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-26 08:50 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-26 08:50 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-26 08:50 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Biotechnology
Location: United States